NEW DELHI: Bharat Biotech announced on Monday that it had resumed exports of its covid-19 vaccine Covaxin, with pending orders being fulfilled in November.
“Long-standing export orders were filled in November, to be further expanded in the following months. With the increase in the number of countries that have granted emergency use authorizations for Covaxin, exports to other countries will also begin from December, ”the Hyderabad-based vaccine maker said in a statement.
On November 3, the World Health Organization (WHO) Technical Advisory Group granted Emergency Use List (EUL) status to Bharat Biotech’s Covaxin. The WHO EUL procedure assesses the quality, safety and efficacy of covid-19 vaccines and is a prerequisite for the supply of COVAX vaccines, a multilateral initiative to promote global access to vaccines against COVAX. covid-19. It also allows countries to speed up their own regulatory approval to import and administer covid-19 vaccines.
Covaxin is a whole virus inactivated SARS-CoV2 vaccine developed in partnership with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV), Pune.
After a hiatus of almost six months, India resumed exports of covid-19 vaccines in October, albeit on a limited basis, with the first shipments going to Iran, Bangladesh, Nepal and Myanmar. officials told Mint.
Iran was one of the first countries to receive one million doses of Covaxin on Saturday. Earlier last week, the Serum Institute of India also announced that it had resumed exports of its Covishield vaccine.
India has so far administered 123 crore doses of covid-19 vaccine, with around 40% of India’s eligible population receiving both doses.
Never miss a story! Stay connected and informed with Mint. Download our app now !!